Abstract
Cardiovascular (CV) comorbidities in patients with chronic obstructive pulmonary disease (COPD) are associated with increased morbidity and mortality, especially in old and very old subjects. The question if long-acting beta-agonist and long-acting muscarinic antagonist could be associated with the increased prevalence of CV-related adverse effects has puzzled, particularly in the past, specialists involved in the management of respiratory diseases. The safety of these compounds has scarcely been tested in patients aged ≥ 65 years with CV comorbidities, since randomized controlled trials rarely include this subpopulation. However, the fixed combination indacaterol/glycopyrronium has shown a favorable CV safety profile in both healthy volunteers and COPD patients. Thus, we aimed to assess the CV safety pro<X00-Del-TrennDivis> - </X00-Del-TrennDivis> file of the fixed combination indacaterol/glycopyrronium 110/50 μg in a series of COPD patients aged ≥ 80 years with several comorbidities. Our results indicate that this combination is safe in the comorbid elderly, since no significant electrocardiographic abnormalities were recorded after the administration of the inhaled therapy. Only rare and nonclinically significant changes in heart rate and corrected QT interval duration were evident, mainly in females and in patients with concomitant impaired kidney function.
| Original language | English |
|---|---|
| Pages (from-to) | 22-29 |
| Number of pages | 8 |
| Journal | Respiration |
| Volume | 95 |
| DOIs | |
| Publication status | Published - Apr 1 2018 |
Fingerprint
Keywords
- Chronic obstructive pulmonary disease
- Elderly
- Indacaterol/glycopyrronium
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
Cite this
Combination Therapy of Inhaled Indacaterol/Glycopyrronium for Chronic Obstructive Pulmonary Disease in the Very Elderly : Is It Safe? An Electrocardiographic Evaluation. / Spannella, Francesco; Giulietti, Federico; Cesari, Valentina; Francioso, Antonio; Cocci, Guido; Landi, Laura; Lombardi, Francesca Elena; Borioni, Elisabetta; Bernardi, Beatrice; Rosettani, Giulia; Bordoni, Valentina; Iacoacci, Corrado; Giordano, Piero; Sarzani, Riccardo.
In: Respiration, Vol. 95, 01.04.2018, p. 22-29.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Combination Therapy of Inhaled Indacaterol/Glycopyrronium for Chronic Obstructive Pulmonary Disease in the Very Elderly
T2 - Is It Safe? An Electrocardiographic Evaluation
AU - Spannella, Francesco
AU - Giulietti, Federico
AU - Cesari, Valentina
AU - Francioso, Antonio
AU - Cocci, Guido
AU - Landi, Laura
AU - Lombardi, Francesca Elena
AU - Borioni, Elisabetta
AU - Bernardi, Beatrice
AU - Rosettani, Giulia
AU - Bordoni, Valentina
AU - Iacoacci, Corrado
AU - Giordano, Piero
AU - Sarzani, Riccardo
PY - 2018/4/1
Y1 - 2018/4/1
N2 - Cardiovascular (CV) comorbidities in patients with chronic obstructive pulmonary disease (COPD) are associated with increased morbidity and mortality, especially in old and very old subjects. The question if long-acting beta-agonist and long-acting muscarinic antagonist could be associated with the increased prevalence of CV-related adverse effects has puzzled, particularly in the past, specialists involved in the management of respiratory diseases. The safety of these compounds has scarcely been tested in patients aged ≥ 65 years with CV comorbidities, since randomized controlled trials rarely include this subpopulation. However, the fixed combination indacaterol/glycopyrronium has shown a favorable CV safety profile in both healthy volunteers and COPD patients. Thus, we aimed to assess the CV safety pro<X00-Del-TrennDivis> - file of the fixed combination indacaterol/glycopyrronium 110/50 μg in a series of COPD patients aged ≥ 80 years with several comorbidities. Our results indicate that this combination is safe in the comorbid elderly, since no significant electrocardiographic abnormalities were recorded after the administration of the inhaled therapy. Only rare and nonclinically significant changes in heart rate and corrected QT interval duration were evident, mainly in females and in patients with concomitant impaired kidney function.
AB - Cardiovascular (CV) comorbidities in patients with chronic obstructive pulmonary disease (COPD) are associated with increased morbidity and mortality, especially in old and very old subjects. The question if long-acting beta-agonist and long-acting muscarinic antagonist could be associated with the increased prevalence of CV-related adverse effects has puzzled, particularly in the past, specialists involved in the management of respiratory diseases. The safety of these compounds has scarcely been tested in patients aged ≥ 65 years with CV comorbidities, since randomized controlled trials rarely include this subpopulation. However, the fixed combination indacaterol/glycopyrronium has shown a favorable CV safety profile in both healthy volunteers and COPD patients. Thus, we aimed to assess the CV safety pro<X00-Del-TrennDivis> - file of the fixed combination indacaterol/glycopyrronium 110/50 μg in a series of COPD patients aged ≥ 80 years with several comorbidities. Our results indicate that this combination is safe in the comorbid elderly, since no significant electrocardiographic abnormalities were recorded after the administration of the inhaled therapy. Only rare and nonclinically significant changes in heart rate and corrected QT interval duration were evident, mainly in females and in patients with concomitant impaired kidney function.
KW - Chronic obstructive pulmonary disease
KW - Elderly
KW - Indacaterol/glycopyrronium
UR - http://www.scopus.com/inward/record.url?scp=85046754992&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046754992&partnerID=8YFLogxK
U2 - 10.1159/000487182
DO - 10.1159/000487182
M3 - Article
C2 - 29705783
AN - SCOPUS:85046754992
VL - 95
SP - 22
EP - 29
JO - Respiration; international review of thoracic diseases
JF - Respiration; international review of thoracic diseases
SN - 0025-7931
ER -